

Episode 113
Aug 27, 2024
The hosts dive into the implications of recent Medicare drug pricing changes and predict how political shifts might impact biotech mergers. They discuss the controversial closing of Genentech's cancer immunology group and Roche's strategic refocusing. Exciting innovations are highlighted, including advances in hypoparathyroidism treatments and new drugs for obesity-related heart failure. The World Health Organization's monkeypox announcement prompts a look at vaccine development, while upcoming lung cancer conferences stir anticipation for groundbreaking data.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Intro
00:00 • 4min
Shifting Sands: Drug Pricing and Political Influence
04:15 • 14min
M&A Trends in Biotech: Challenges and Outlook
18:34 • 6min
Roche's Strategic Shift in Oncology
24:31 • 10min
Emerging Innovations in Hypoparathyroidism and Growth Hormone Therapies
34:02 • 4min
Monkeypox, Weight Loss Journeys, and Biotech Innovations
37:47 • 14min
Innovative Strategies for CNS Drug Delivery: The Role of Oligonucleotide Transport Vehicles
51:31 • 5min
Anticipating Key Lung Cancer Data from Upcoming Conferences
56:04 • 4min